Literature DB >> 32205187

Comparative toxicokinetics of Trans-resveratrol and its major metabolites in Harlan Sprague Dawley rats and B6C3F1/N mice following oral and intravenous administration.

Esra Mutlu1, Seth T Gibbs2, Natalie South2, Jessica Pierfelice2, Brian Burback2, Dori Germolec3, Suramya Waidyanatha3.   

Abstract

Trans-resveratrol (RES) is a naturally occurring stilbene found in numerous plants and foods. Due to its widespread human exposure and lack of toxicity and carcinogenicity data, RES was nominated to the National Toxicology Program for testing. To aid the toxicology studies, the dose, sex, and species differences in RES toxicokinetics was investigated in Harlan Sprague Dawley rats and B6C3F1/N mice following single intravenous (IV) (10 mg/kg) or oral gavage administration (312.5, 625, and 1250 mg/kg and 625, 1250, and 2500 mg/kg in rats and mice, respectively). Following IV and gavage administration, systemic exposure of RES based on AUC was trans-resveratrol-3-O-β-D-glucuronide (R3G)> > trans-resveratrol-3-sulfate (R3S) > RES in both species. Following gavage administration Tmax_predicted values were ≤ 263 min for both species and sexes. RES elimination half-life was longer in rats than mice, and shortest in male mice. Clearance was slower in mice with no apparent sex difference in both species. In both rats and mice, following gavage administration AUC increased proportionally to the dose. After gavage administration, enterohepatic recirculation of RES was observed in both rats and mice with secondary peaks occurring around 640 min in the concentration-time profiles. RES was rapidly metabolized to R3S and R3G in both species. Extensive first pass conjugation and metabolism resulted in low levels of the parent compound RES which was confirmed by the low estimates for bioavailability. The bioavailability of RES was low, ~12-31% and ~2-6% for rats and mice, respectively, with no apparent difference between sexes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Plasma; Resveratrol; Resveratrol-3-glucorinide; Resveratrol-3-sulfate; Toxicokinetics

Mesh:

Substances:

Year:  2020        PMID: 32205187      PMCID: PMC7398575          DOI: 10.1016/j.taap.2020.114962

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  61 in total

1.  Pleiotropic mechanisms facilitated by resveratrol and its metabolites.

Authors:  Barbara Calamini; Kiira Ratia; Michael G Malkowski; Muriel Cuendet; John M Pezzuto; Bernard D Santarsiero; Andrew D Mesecar
Journal:  Biochem J       Date:  2010-07-15       Impact factor: 3.857

2.  Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity.

Authors:  W D Johnson; R L Morrissey; A L Usborne; I Kapetanovic; J A Crowell; M Muzzio; D L McCormick
Journal:  Food Chem Toxicol       Date:  2011-09-10       Impact factor: 6.023

3.  Resveratrol suppresses colitis and colon cancer associated with colitis.

Authors:  Xiangli Cui; Yu Jin; Anne B Hofseth; Edsel Pena; Joshua Habiger; Alexander Chumanevich; Deepak Poudyal; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh; Lorne J Hofseth
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

Review 4.  Metabolism and bioavailability of trans-resveratrol.

Authors:  Elisabeth Wenzel; Veronika Somoza
Journal:  Mol Nutr Food Res       Date:  2005-05       Impact factor: 5.914

5.  Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats.

Authors:  A A Bertelli; L Giovannini; R Stradi; A Bertelli; J P Tillement
Journal:  Int J Tissue React       Date:  1996

6.  Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats.

Authors:  Izet M Kapetanovic; Miguel Muzzio; Zhihua Huang; Thomas N Thompson; David L McCormick
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-30       Impact factor: 3.333

7.  Resveratrol: phytoestrogen effects on reproductive physiology and behavior in female rats.

Authors:  Lisa A Henry; Diane M Witt
Journal:  Horm Behav       Date:  2002-03       Impact factor: 3.587

8.  Inhibition of cancer growth by resveratrol is related to its low bioavailability.

Authors:  Miguel Asensi; Ignacio Medina; Angel Ortega; Julian Carretero; M Carmen Baño; Elena Obrador; Jose M Estrela
Journal:  Free Radic Biol Med       Date:  2002-08-01       Impact factor: 7.376

9.  Safety studies conducted on high-purity trans-resveratrol in experimental animals.

Authors:  Lonnie D Williams; George A Burdock; James A Edwards; Mareike Beck; Jochen Bausch
Journal:  Food Chem Toxicol       Date:  2009-06-06       Impact factor: 6.023

10.  Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.

Authors:  David J Boocock; Guy E S Faust; Ketan R Patel; Anna M Schinas; Victoria A Brown; Murray P Ducharme; Tristan D Booth; James A Crowell; Marjorie Perloff; Andreas J Gescher; William P Steward; Dean E Brenner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  4 in total

1.  AKT/foxo3a signal pathway mediates the protective mechanism of resveratrol on renal interstitial fibrosis and oxidative stress in rats with unilateral ureteral obstruction.

Authors:  Rongrong Sun; Qu Zheng
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

2.  Resveratrol Ameliorates Systemic Sclerosis via Suppression of Fibrosis and Inflammation Through Activation of SIRT1/mTOR Signaling.

Authors:  Qicen Yao; Qingchao Wu; Xiayu Xu; Yixi Xing; Jin Liang; Qianqi Lin; Meiqiong Huang; Yiling Chen; Bo Lin; Weifei Chen
Journal:  Drug Des Devel Ther       Date:  2020-12-02       Impact factor: 4.162

3.  Immunotoxicity studies of trans-resveratrol in male B6C3F1/N mice.

Authors:  Madelyn C Huang; Kimber L White; Susan A Elmore; Tai L Guo; Dori Germolec
Journal:  J Immunotoxicol       Date:  2020-12       Impact factor: 3.000

4.  Resveratrol and Its Analogue 4,4'-Dihydroxy-trans-stilbene Inhibit Lewis Lung Carcinoma Growth In Vivo through Apoptosis, Autophagy and Modulation of the Tumour Microenvironment in a Murine Model.

Authors:  Monica Savio; Alessandra Ferraresi; Chiara Corpina; Sara Vandenberghe; Chiara Scarlata; Virginie Sottile; Luca Morini; Beatrice Garavaglia; Ciro Isidoro; Lucia Anna Stivala
Journal:  Biomedicines       Date:  2022-07-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.